相关临床试验
280
20 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1847
进行中（未招募）
14
5.0%
已完成
177
63.2%
Enrolling By Invitation
2
0.7%
No Longer Available
1
0.4%
尚未招募
4
1.4%
招募中
32
11.4%
终止
31
11.1%
撤回
19
6.8%
暂无批准数据
- The National Science Foundation has awarded $15 million over two years to the RuralSTAMINA initiative, with potential for up to $160 million over 10 years, to build a bioeconomy innovation ecosystem across Nebraska and Iowa. - RuralSTAMINA brings together approximately 70 public and private partners, including the University of Nebraska-Lincoln and Iowa State University, to advance biomass conversion and biomanufacturing. - The initiative aims to develop specialty products including pharmaceuticals, animal vaccines, and biologics while creating workforce development pathways from K-12 through higher education. - The global bioeconomy market, currently valued at approximately $4 trillion, is projected to grow to $10 trillion within the next five to ten years, positioning the region for competitive advantage.
- A University of Iowa team led by David Stoltz received nearly $12 million over five years from the NIH to develop new treatments for primary ciliary dyskinesia (PCD), an inherited disease causing chronic respiratory infections and progressive lung damage. - The research aims to first understand how PCD develops, then test whether gene editing can treat the underlying causes of the disease rather than just its symptoms. - Many PCD patients are not diagnosed until childhood or adulthood because newborns are not routinely screened, by which time recurring infections may have already caused lasting damage. - The long-term goal is to create new treatments that help people with PCD live longer, healthier lives, building on Iowa's internationally recognized work in cystic fibrosis.
- Motif Neurotech received FDA approval for the RESONATE early feasibility study to test its XCS System, a wirelessly-powered brain implant for treatment-resistant depression. - The blueberry-sized device delivers electrical stimulation to brain regions without direct brain contact, activated by wearing a baseball hat-like external component. - The trial will evaluate safety and efficacy in patients who have not responded to two or more medications across eight leading medical institutions. - Nearly 3 million Americans live with treatment-resistant depression, representing a significant unmet medical need for this novel brain-computer interface approach.
- A large real-world clinical trial involving 384 fibromyalgia patients across 28 clinics found that adding TENS to physical therapy significantly reduced movement-evoked pain by 1.2 points on a 10-point scale compared to physical therapy alone. - The study demonstrated that TENS therapy specifically targets both movement-associated pain and fatigue, with 72% of patients reporting improvement compared to 51% receiving physical therapy only. - Unlike traditional pain medications that lose effectiveness over time, TENS maintained its therapeutic benefits for at least six months, with 81% of participants finding it helpful and 55% using it daily at the study's end. - The treatment showed a dose-dependent response with no serious adverse events, positioning TENS as a safe, accessible, and cost-effective addition to fibromyalgia management protocols.
- Three scientists, including Vertex's Paul Negulescu, received the 2025 Lasker-DeBakey Clinical Medical Research Award for developing TRIKAFTA, a life-saving triple-drug combination therapy for cystic fibrosis. - The breakthrough treatment extends lifespans of CF patients by decades, with those starting treatment in childhood expected to live near-average lifespans compared to a median survival age of 40 before 2019. - TRIKAFTA addresses the underlying molecular cause of CF by combining three drugs that help restore proper ion transport in cells, fundamentally changing how this genetic disease is treated. - Vertex's CF medicines now treat over 75,000 people across more than 60 countries, representing approximately two-thirds of diagnosed CF patients eligible for CFTR modulator therapy.
- University of Iowa researchers successfully developed a gene therapy using miR-200a delivered via 95-nanometer packets that prevented craniosynostosis in all eight genetically programmed infant mice tested. - The treatment could replace invasive cranial vault remodeling surgery, which currently requires removing and reshaping skull bones and carries risks including blood transfusion needs, ICU stays, and rare fatalities. - The research team has applied to the FDA for human clinical trials and aims to begin testing in infants within one to two years, pending approval and additional safety studies. - Craniosynostosis affects approximately 1 in 2,000 to 2,200 babies when skull bones fuse prematurely, potentially causing abnormal head shape and impaired brain growth if untreated.
- NIH-funded preclinical research demonstrates that uric acid treatment significantly improved sensorimotor function and survival rates in rodents 30 days after ischemic stroke. - The study, conducted by University of Iowa researchers, showed efficacy across diverse animal groups including different ages, sexes, and those with comorbidities like obesity and hypertension. - As part of the NIH's Stroke Preclinical Assessment Network (SPAN), uric acid emerged as the only effective agent among six promising stroke treatments tested, suggesting readiness for human clinical trials.
- A study using the Enroll-HD database found that beta-blocker use is associated with delayed motor diagnosis in premanifest Huntington's disease (HD). - In patients with early motor symptoms of HD, beta-blockers correlated with slower progression of motor symptoms and cognitive decline. - Unlike ACE inhibitors, beta-blockers showed a specific positive association with HD, suggesting benefits beyond treating cardiovascular issues. - The study highlights correlation, not causation, necessitating further clinical trials to confirm the effects of beta-blockers on HD.
